These findings indicate that TQ, by reducing DNA methylation of genes that negatively regulate the JAK/STAT pathway, may represent a promising therapeutic alternative for the treatment of patients suffering from CML in the future. The gene discussed is SOAT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.